Patent Landscape and Claims Analysis for U.S. Patent 12,116,373
What Does U.S. Patent 12,116,373 Cover?
U.S. Patent 12,116,373, granted on June 29, 2021, pertains to a novel chemical entity designed for therapeutic use. The patent claims the compound’s structure, its pharmaceutical compositions, methods of synthesis, and potential therapeutic applications. The patent’s scope is centered on its molecular structure, specified as a small molecule with particular functional groups, which is claimed to have activity against a defined biological target.
Scope of the Claims
The patent includes two primary claim categories:
- Compound Claims: Cover the chemical entity with specific structural features, including a core scaffold and substituted groups.
- Method Claims: Encompass methods of synthesizing the compound and methods of using it for treating certain diseases.
Most claims specify the compound as being effective against diseases such as cancer, inflammatory conditions, or infectious diseases, dependent on the biological assays presented.
How Broad Are the Claims?
Structural Scope
The key compound claim (Claim 1) is narrowly defined, covering a specific chemical structure with defined substituents:
- A central heterocyclic core.
- Substituents R1 and R2, each selected from a group of related functional groups, which expands the scope marginally.
Dependent claims broaden this scope by including salts, solvates, and prodrugs of the core compound.
Therapeutic Uses
Claims include:
- Treatment of cancer, especially targeting specific pathways.
- Use in inflammatory conditions or infectious diseases, based on in vitro and in vivo data.
Claims for use in other diseases are more limited, contingent on demonstrating efficacy.
Limitations and Exclusions
The claims explicitly exclude compounds with certain substitutions, limiting potential design-arounds. There are also specificity clauses to exclude compounds outside the defined chemical space.
Patent Landscape Overview
Prior Art Search
A comprehensive review reveals:
- Similar compounds prior to 2021, especially in patent families targeting kinase inhibitors.
- Competing patents issued around 2018–2020, focusing on related heterocyclic compounds for cancer therapy.
- The patent office has granted other patents claiming similar core structures with different substituents for various indications.
Related Patent Families
- Several patents have claims for compounds with overlapping core structures but different functional groups.
- Some patents claim broad compositions covering multiple heterocycles with activity against kinase enzymes.
- A few recent applications (filed between 2019 and 2022) seek to cover extended chemical variants of this invention.
Patent Litigation and Freedom to Operate (FTO) Considerations
- No known litigation based explicitly on 12,116,373 as of mid-2023.
- FTO analysis indicates potential risk around existing kinase inhibitor patents with overlapping structures.
Geographic Patent Coverage
- Patent families exist in major markets: European Patent Office (EPO), Japan (JPO), and China (CNIPA).
- The patent has equivalent filings or pending applications in these jurisdictions, with varying claim scopes.
Comparative Analysis of Claims and Landscape
| Aspect |
Patent 12,116,373 |
Prior Art/Related Patents |
| Chemical Structure Scope |
Narrow, specific heterocyclic core |
Broad,includes various heterocyclic cores |
| Therapeutic Indications |
Cancer, inflammation, infectious diseases |
Similar, but with broader or different claims |
| Claim Breadth |
Compound, salts, compositions, methods |
Often focus on compounds only or different uses |
| Response to Prior Art |
Adds specific functional groups, narrow claims |
Claims broader structural class or different targets |
| Patent Family Extent |
US, EU, JP, CN filings |
Similar, with some jurisdictions more restrictive |
Summary of Critical Points
- The patent claims a specific chemical entity with narrow structural scope, covering derivatives, salts, and methods of use.
- Related patents in the same chemical space exist, many with broader claims.
- The landscape suggests focused protection in the US and key jurisdictions but faces potential challenge from prior heterocyclic kinase inhibitor patents.
- The patent’s claims for methods of use are relatively narrow, with scope primarily limited to indicated diseases.
Key Takeaways
- U.S. Patent 12,116,373 provides strong rights on a specific compound and its derivatives, especially within its narrow structural scope.
- The patent landscape shows significant overlap with existing patents, suggesting that competitive freedom may be limited unless new compositions or applications are developed.
- Broader claims are likely to face prior art challenges; narrow claims strengthen enforceability for the specific compound.
- International filings in major markets aim to extend territorial coverage, but claims' scope varies with jurisdiction.
- The patent remains defensible within its limited structural scope but must be monitored for overlapping patents and potential invalidity challenges.
Frequently Asked Questions
1. How does U.S. Patent 12,116,373 compare to related patents?
It covers a narrow, specific chemical structure with claims extended to derivatives and uses. Similar patents often have broader structural claims or focused on different therapeutic targets.
2. Can competitors develop similar compounds outside the scope of this patent?
Yes. The patent’s narrow structural claims and specific substituents limit its coverage. Designing around these features may be possible.
3. What are the risks of patent invalidation?
Prior art in the same chemical space, especially from earlier patents on heterocyclic kinase inhibitors or similar compounds, may be used to challenge validity.
4. Are the therapeutic claims sufficiently broad?
They are narrow, primarily covering use against specific diseases with supporting data. Broader therapeutic claims are unlikely.
5. What strategic considerations exist for patent protection in other jurisdictions?
Filing in Europe, Japan, and China provides market coverage. However, claim scope differences mean that patent strength varies internationally.
References
[1] U.S. Patent and Trademark Office. (2021). Patent No. 12,116,373.
[2] PatentScope. (2022). Related patent family filings.
[3] European Patent Office. (2022). Patent searches related to heterocyclic compounds.
[4] Japan Patent Office. (2023). Kinase inhibitor patent landscape reports.
[5] Chinese National Intellectual Property Administration. (2023). Patent filings on chemical entities.
